All lobbying filings

TIBER CREEK HEALTH STRATEGIES, INC.

Lobbying for NOVARTIS · Pharmaceutical manufacturer.

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 17, 2025

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 1

SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act (118th Congress).

Health Issues

Issues related to PBM reform.

Bills named in this filing 2

H.R. 5547
Maintaining Investments in New Innovation Act
S. 476
Maintaining Investments in New Innovation Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.